FRONT ONCOL 2021 10.3389/fonc.2021.596364

Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry

Kim¹, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH

CANCER 2021 10.1002/cncr.33571

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program

Park¹, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

FRONT ONCOL 2021 10.3389/fonc.2021.653243

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study

Lee¹, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH

J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Lee¹, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI

DIAGNOSTICS 2021 10.3390/diagnostics11020370

Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea

Hong¹, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH

EUR J IMMUNOL 2021 10.1002/eji.202048966

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

Ku¹, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

Kim¹, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN APPL THROMB-HEM 2021 10.1177/1076029620979575

Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study

Bang¹, SM; Kang, JH; Hong, MH; Ahn, JS; Oh, SY; Baek, JH; Choi, YJ; Shin, SH; Kim, YJ; Gil, H; Park, HE; Lee, J; Park, EL

IMMUNE NETW 2020 10.4110/in.2020.20.e48

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Kim¹, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

SCI REP-UK 2020 10.1038/s41598-020-76130-1

Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Koh¹, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee¹, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2020 10.4143/crt.2020.278

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park¹, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

BIOLOGY-BASEL 2020 10.3390/biology9100326

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?

Jung¹, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

Jung¹, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Hong¹, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

ANN ONCOL 2020 10.1016/j.annonc.2020.06.017

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Park¹, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC DIS 2020 10.21037/jtd-20-1671

Characteristics of female lung cancer in Korea analysis of Korean National Lung Cancer Registry

Lim¹, JU; Han, S; Kim, HC; Choi, CM; Jung, CY; Cho, DG; Jeon, JH; Lee, JE; Ahn, JS; Kim, Y; Choi, YD; Suh, YG; Kim, JE; Won, YJ; Kim, YC; Park, CK; Kim, SJ

MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108

Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer

Park¹, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH

SCI REP-UK 2020 10.1038/s41598-020-70168-x

Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations

Kim¹, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH

EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Kim¹, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Jung¹, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K

BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1

Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer

Kim¹, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH

ANN ONCOL 2020 10.1016/j.annonc.2020.04.478

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Mok¹, T; Camidge, DR; Gadgeel, SM; Rosell, R; Dziadziuszko, R; Kim, DW; Perol, M; Ou, SHI; Ahn, JS; Shaw, AT; Bordogna, W; Smoljanovic, V; Hilton, M; Ruf, T; Noe, J; Peters, S

LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033

Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)

Jung¹, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

ANN ONCOL 2020 10.1016/j.annonc.2020.04.004

HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients

Shim¹, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Lee¹, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC DIS 2020 10.21037/jtd.2019.08.29

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2020 10.4143/crt.2019.713

Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting

Kang¹, JH; Kwon, JH; Lee, YG; Park, KU; An, HJ; Sohn, J; Seol, YM; Lee, H; Yun, HJ; Ahn, JS; Yang, JH; Song, H; Koo, DH; Kim, JY; Kim, GM; Kim, HJ

CANCER 2020 10.1002/cncr.32809

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer

Lee¹, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

EUR J CANCER 2020 10.1016/j.ejca.2020.03.029

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

Lee¹, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NAT COMMUN 2020 10.1038/s41467-020-16164-1

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Kim¹, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

IN VIVO 2020 10.21873/invivo.11920

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

Hur¹, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests

Byeon¹, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

CANCERS 2020 10.3390/cancers12051306

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience

Hur¹, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH

J PAIN SYMPTOM MANAG 2020

Reliability and Validity of the Korean Language Version of the US National Cancer Institute?s Patient -Reported Outcomes Common Terminology Criteria for Adverse Events

Yoon¹, J; Sim, SH; Kang, D; Han, G; Kim, Y; Ahn, J; Oh, D; Lee, ES; Kong, SY; Cho, J; Mitchell, SA

SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z

Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)

Kang¹, D; Kim, IR; Park, YH; Im, YH; Zhao, D; Guallar, E; Ahn, JS; Cho, J

INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Ku¹, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Cancer Med 2020 10.1002/cam4.2868

PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence

Byeon¹, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.19.00457

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

Yang¹, JCH; Kim, SW; Kim, DW; Lee, JS; Cho, BC; Ahn, JS; Lee, DH; Kim, TM; Goldman, JW; Natale, RB; Brown, AP; Collins, B; Chmielecki, J; Vishwanathan, K; Mendoza-Naranjo, A; Ahn, MJ

J CLIN ONCOL 2020 10.1200/JCO.19.00931

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Cho¹, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2020 10.4143/crt.2019.186

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

Lee¹, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

LUNG CANCER 2020 10.1016/j.lungcan.2019.10.015

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

Ou¹, SHI; Gadgeel, SM; Barlesi, F; Yang, JCH; De Petris, L; Kim, DW; Govindan, R; Dingemans, AM; Crino, L; Lena, H; Popat, S; Ahn, JS; Dansin, E; Mitry, E; Muller, B; Bordogna, W; Balas, B; Morcos, PN; Shaw, AT

BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Shin¹, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

Oncoimmunology 2020 10.1080/2162402X.2020.1722023

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Kim¹, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Park¹, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA

LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn¹, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC

INT J CANCER 2019 10.1002/ijc.32235

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

Shin¹, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH

EUR J CANCER 2019 10.1016/j.ejca.2019.08.001

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing

Kim¹, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

CANCER RES TREAT 2019 10.4143/crt.2018.704

Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

Choi¹, CM; Kim, HC; Jung, CY; Cho, DG; Jeon, JH; Lee, JE; Ahn, JS; Kim, SJ; Kim, Y; Choi, YD; Suh, YG; Kim, JE; Lee, B; Won, YJ; Kim, YC

NAT COMMUN 2019 10.1038/s41467-019-12159-9

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung¹, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim¹, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Park¹, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy

Heo¹, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH

LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma

Park¹, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Cho¹, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

SCI REP-UK 2019 10.1038/s41598-019-48674-4

Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY

JAMA Oncol 2019 10.1001/jamaoncol.2019.0339

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

Jackisch¹, C; Stroyakovskiy, D; Pivot, X; Ahn, JS; Melichar, B; Chen, SC; Meyenberg, C; Al-Sakaff, N; Heinzmann, D; Hegg, R

J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Park¹, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

Cho¹, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CANCER RES TREAT 2019 10.4143/crt.2018.262

Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data

Kim¹, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF

LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer

Lee¹, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

CANCER RES TREAT 2019 10.4143/crt.2018.342

Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance

Kim¹, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH

CANCER RES TREAT 2019 10.4143/crt.2018.324

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo¹, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.117

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim¹, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

CANCER RES TREAT 2019 10.4143/crt.2018.125

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Park¹, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449

The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim¹, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC

CANCER RES TREAT 2019 10.4143/crt.2018.151

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon¹, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

CANCER RES TREAT 2019 10.4143/crt.2018.366

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer

Lee¹, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

ONCOLOGIST 2019 10.1634/theoncologist.2018-0184

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study

Kang¹, D; Kim, IR; Choi, EK; Im, YH; Park, YH; Ahn, JS; Lee, JE; Nam, SJ; Lee, HK; Park, JH; Lee, DY; Lacouture, ME; Guallar, E; Cho, J

ONCOL LETT 2019 10.3892/ol.2018.9754

Clinical features and prognosis of breast cancer with gastric metastasis

Hong¹, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH

MEDICINE 2019 10.1097/MD.0000000000014278

Sedation for terminally ill cancer patients A multicenter retrospective cohort study in South Korea

Kim¹, YS; Song, HN; Ahn, JS; Koh, SJ; Ji, JH; Hwang, IG; Yun, J; Kwon, JH; Kang, JH

J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim¹, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

CLIN NUCL MED 2019 10.1097/RLU.0000000000002394

Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification

Moon¹, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY

EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5

Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer

Moon¹, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH

HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3

The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans

Kim¹, H; Choi, DH; Park, W; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Jung, BY

CANCER RES TREAT 2019 10.4143/crt.2018.138

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer

Lee¹, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ

BMC CANCER 2019 10.1186/s12885-018-5258-9

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea

Kim¹, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH

BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x

A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients

Hwang¹, HW; Jung, H; Hyeon, J; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Lee, SK; Choi, M; Cho, SY; Cho, EY

J BREAST CANC 2018 10.4048/jbc.2018.21.e48

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis

Seo¹, Y; Park, YH; Ahn, JS; Im, YH; Nam, SJ; Cho, SY; Cho, EY

INT J CANCER 2018 10.1002/ijc.31651

A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial

Park¹, YH; Lee, KH; Sohn, JH; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Ahn, JS; Kim, TY; Kim, GM; Park, IH; Kim, SB; Kim, SH; Han, HS; Im, YH; Ahn, JH; Kim, JY; Kang, J; Im, SA

EUR J CANCER 2018 10.1016/j.ejca.2018.08.004

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)

Kim¹, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH

CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010

Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment

Cho¹, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S

BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z

Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort

Kim¹, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH

LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Lim¹, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice

Park¹, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009

Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma

Lee¹, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM

J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Lee¹, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ

J BREAST CANC 2018 10.4048/jbc.2018.21.2.206

Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?

Cho¹, WK; Park, W; Choi, DH; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY

Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Tan¹, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K

ASIA-PAC J CLIN ONCO 2018 10.1111/ajco.12696

Inadequate treatment practices for pain relief and adverse eventmanagement in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care

Ho¹, KY; Ahn, JS; Calimag, MM; Chao, TC; Kim, YC; Moon, H; Tho, LM; Xia, ZJ; You, DR

AM J HEMATOL 2018 10.1002/ajh.25043

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Gambacorti-Passerini¹, C; Orlov, S; Zhang, L; Braiteh, F; Huang, HQ; Esaki, T; Horibe, K; Ahn, JS; Beck, JT; Edenfield, WJ; Shi, YK; Taylor, M; Tamura, K; Van Tine, BA; Wu, SJ; Paolini, J; Selaru, P; Kim, TM

LUNG CANCER 2018 10.1016/j.lungcan.2018.02.020

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea

Choi¹, MK; Ahn, JS; Kim, YC; Cho, BC; Oh, IJ; Kim, SW; Lee, JS; Kim, JH; Ahn, MJ; Park, K

Oncoimmunology 2018 10.1080/2162402X.2018.1466768

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer

Park¹, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH

PLoS One 2018 10.1371/journal.pone.0194730

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

Ku¹, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

NAT COMMUN 2018 10.1038/s41467-018-04129-4

Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures

Kan¹, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH

BRIT J CANCER 2018 10.1038/bjc.2017.465

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sun¹, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy

Park¹, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J

J BREAST CANC 2018 10.4048/jbc.2018.21.1.91

Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy

Park¹, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Cho¹, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer

Cho¹, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011

Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Park¹, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

BMC CANCER 2018 10.1186/s12885-017-3965-2

A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors

Park¹, E; Yoon, J; Choi, EK; Kim, IR; Kang, D; Lee, SK; Lee, JE; Nam, SJ; Ahn, JS; Visser, A; Cho, J

LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer

Lee¹, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J

J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer

Sun¹, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K

Lancet Respir Med 2017 10.1016/S2213-2600(17)30378-8

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study

Ahn¹, MJ; Kim, DW; Cho, BC; Kim, SW; Lee, JS; Ahn, JS; Kim, TM; Lin, CC; Kim, HR; John, T; Kao, S; Goldman, JW; Su, WC; Natale, R; Rabbie, S; Harrop, B; Overend, P; Yang, ZF; Yang, JCH

NAT COMMUN 2017 10.1038/s41467-017-01470-y

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

CANCER RES TREAT 2017 10.4143/crt.2016.442

Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience

Park¹, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM

EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

Ku¹, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

J THORAC ONCOL 2017 10.1016/j.jtho.2017.06.070

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

Yang¹, JCH; Ou, SHI; De Petris, L; Gadgeel, S; Gandhi, L; Kim, DW; Barlesi, F; Govindan, R; Dingemans, AMC; Crino, L; Lena, N; Popat, S; Ahn, JS; Dansin, E; Golding, S; Bordogna, W; Batas, B; Morcos, PN; Zeaiter, A; Shaw, AT

ONCOTARGET 2017

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

Ku¹, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ

BREAST CANCER RES TR 2017 10.1007/s10549-017-4304-7

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

Cortes¹, J; Rugo, HS; Awada, A; Twelves, C; Perez, EA; Im, SA; Gomez-Pardo, P; Schwartzberg, LS; Dieras, V; Yardley, DA; Potter, DA; Mailliez, A; Moreno-Aspitia, A; Ahn, JS; Zhao, C; Hoch, U; Tagliaferri, M; Hannah, AL; O'Shaughnessy, J

CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

Kim¹, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Chin J Cancer 2017 10.1186/s40880-017-0241-4

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial

Lee¹, KH; Kim, TW; Kang, JH; Kim, JS; Ahn, JS; Kim, SY; Yun, HJ; Eum, YJ; Koh, SA; Kim, MK; Hong, YS; Kim, JE; Lee, GW

ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652

Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy

Kim¹, H; Park, W; Huh, SJ; Choi, DH; Noh, JM; Im, YH; Ahn, JS; Park, YH; Nam, SJ; Kim, SW; Lee, JE; Cho, EY

NEW ENGL J MED 2017 10.1056/NEJMoa1704795

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer

Peters¹, S; Camidge, DR; Shaw, AT; Gadgeel, S; Ahn, JS; Kim, DW; Ou, SHI; Perol, M; Dziadziuszko, R; Rosell, R; Zeaiter, A; Mitry, E; Golding, S; Balas, B; Noe, J; Morcos, PN; Mok, T

J Pain Res 2017 10.2147/JPR.S140320

Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review

Ahn¹, JS; Lin, J; Ogawa, S; Yuan, C; O'Brien, T; Le, BHC; Bothwell, AM; Moon, H; Hadjiat, Y; Ganapathi, A

BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7

A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy

Kim¹, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH

ONCOTARGET 2017 10.18632/oncotarget.17653

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response

Kim¹, JY; Lee, E; Park, K; Park, WY; Jung, HH; Ahn, JS; Im, YH; Park, YH

Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

Twelves C1¹, Cortes J2, O'Shaughnessy J3, Awada A4, Perez EA5, Im SA6, Gomez-Pardo P7, Schwartzberg LS8, Dieras V9, Yardley DA10, Potter DA11, Mailliez A12, Moreno-Aspitia A13, Ahn JS14, Zhao C15, Hoch U15, Tagliaferri M15, Hannah AL16, Rugo HS17.

Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes

Kim JY1¹, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.

Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn MJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.

Osimertinib for the treatment of non-small cell lung cancer

Sun JM1¹, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer

Kim JY1¹, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.

Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

Lee JH1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.

EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652

Pembrolizumab for the treatment of non-small cell lung cancer

Lim SH¹, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.

Prognostic value of ERBB4 expression in patients with triple negative breast cancer

Kim JY1¹, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.

PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016.

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)

Lee JY1¹, Lim SH1, Lee MY1, Kim HS1, Ahn JS1, Im YH1, Park YH1.

J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision

Ahn MJ1¹, Sun JM2, Lee SH2, Ahn JS2, Park K2.

J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14.

Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?

Kim H1¹, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.

Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11.

Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems

Choi M1¹, Park YH2, Ahn JS2, Im YH2, Nam SJ3, Cho SY4, Cho EY5.

J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25.

The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations

Cha YK1¹, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.

World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24.

Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer

Choi JW1¹, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.

Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.

Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study

Lim SH1¹, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26.

Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor

Moon SH1¹, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.

Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer

Kim JY1¹, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.

Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.

Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea

Kim HK1¹, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.

Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency

Jung HH1¹, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.

PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016.

Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series

Lee MY1¹, Chang WJ1, Kim HS1, Lee JY1, Lim SH1, Lee JE2, Kim SW2, Nam SJ2, Ahn JS1, Im YH1, Park YH1.

SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804

The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment

Kim JY¹, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH

Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Ku BM1¹, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

Byeon S1¹, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Eur J Cancer. 2016 Jul;62:62-75. doi: 10.1016/j.ejca.2016.03.087. Epub 2016 May 20.

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up

Jackisch C1¹, Hegg R2, Stroyakovskiy D3, Ahn JS4, Melichar B5, Chen SC6, Kim SB7, Lichinitser M8, Staros��awska E9, Kunz G10, Falcon S11, Chen ST12, Crepelle-Flechais A13, Heinzmann D13, Shing M14, Pivot X15.

J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24.

Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes

Kim SW1¹, Choi DH2, Huh SJ2, Park W2, Nam SJ3, Kim SW3, Lee JE3, Im YH4, Ahn JS4, Park YH4.

Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11.

Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes

Yu JI1¹, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.

Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)

Lim SM1¹,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.

Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria

Kim HS1¹, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.

Gene Expression Profiling of Breast Cancer Brain Metastasis

Lee JY1¹, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.

Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee JY1¹, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study

Ou SH1¹, Ahn JS2, De Petris L2, Govindan R2, Yang JC2, Hughes B2, Lena H2, Moro-Sibilot D2, Bearz A2, Ramirez SV2, Mekhail T2, Spira A2, Bordogna W2, Balas B2, Morcos PN2, Monnet A2, Zeaiter A2, Kim DW2.

JOURNAL OF CLINICAL ONCOLOGY, MAR 1 2016, 34(7):768-+, DOI: 10.1200/JCO.2015.65.1042

Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer Reply

Ahn JS¹, Park K

Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Ku BM1¹, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Lee JY1¹, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

Oncotarget. 2015 Sep 15;6(27):24499-510.

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay

Park K1¹, Choi MK2, Jung HH3, Do IG4, Lee KH5, Ahn T1, Kil WH6, Kim SW6, Lee JE6, Nam SJ6, Kim DH7, Ahn JS2, Im YH2,3, Park YH2,3.

J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

Sun JM1¹, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.

J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04

Ahn JS1¹, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.

J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Lee JY1¹, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.

Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.

BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer

Ku BM1¹, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.

Oncologist. 2015 Dec;20(12):1440-7. doi: 10.1634/theoncologist.2015-0128. Epub 2015 Oct 28.

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21

Kim HJ1¹, Shin SW2, Song EK3, Lee NR3, Kim JS4, Ahn JS5, Yun HJ6, Cho YH7, Park KU8, Kim SY9, Jang JS10, Kim SW11, Lee HW12, Lee SR13, Kim YS14, Lee SN15, Ko YH16, Kim HJ17, Kang JH18.

Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.

Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer

Lee JY1¹, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.

Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18.

Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments

Yu JI1¹, Park W2, Choi DH1, Huh SJ1, Nam SJ3, Kim SW3, Lee JE3, Kil WH3, Im YH4, Ahn JS4, Park YH4, Cho EY5.

J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

Kim HS1¹, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs

Lee SJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15.

Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer

Cho KR1¹, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.

Lancet Oncol. 2015 Nov;16(15):1556-68. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial

Perez EA1¹, Awada A2, O'Shaughnessy J3, Rugo HS4, Twelves C5, Im SA6, Gomez-Pardo P7, Schwartzberg LS8, Dieras V9, Yardley DA10, Potter DA11, Mailliez A12, Moreno-Aspitia A13, Ahn JS14, Zhao C15, Hoch U15, Tagliaferri M15, Hannah AL16, Cortes J17.

Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13.

Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer

Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Kim M1, Kim S1, Jung HA1, Sohn I2, Gil WH3, Lee JE3, Kim SW3, Nam SJ3, Ahn JS1, Im YH1, Park YH1.

ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131

Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

Park S¹, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ

Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12.

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer

Noh JM1¹, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.

Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Kim ST1¹, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.

Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer

Park YH1¹,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.

Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29.

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Sun JM1¹, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.

Cancer Med. 2015 Aug;4(8):1196-204. doi: 10.1002/cam4.471. Epub 2015 Apr 27.

Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries

ACHEON Working Group¹, Kim YC1, Ahn JS2, Calimag MM3, Chao TC4,5, Ho KY6, Tho LM7, Xia ZJ8, Ward L9, Moon H10, Bhagat A10.

Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22.

Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study

Kang D1¹, Kim IR, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Park H, Kim E, Lee HK, Lee DY, Cho J.

Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2.

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Park YH1¹, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh do Y, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Woo SY, Jung SH, Ahn JS; Korean Cancer Study Group (KCSG), Im YH.

Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3.

A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients

Kim JE1¹, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW.

Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23.

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

Choi MK1¹, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.

Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24.

Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea

Park YH1¹, Lee SJ1, Jung HA1, Kim SM1, Kim MJ1, Kil WH2, Lee JE2, Nam SJ2, Ahn JS1, Im YH3.

Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Lim SH1¹, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.

Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.

A seven-gene signature can predict distant recurrence in patients with triple- negative breast cancers who receive adjuvant chemotherapy following surgery

Park YH1¹, Jung HH, Do IG, Cho EY, Sohn I, Jung SH, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH.

J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27.

Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer

Yu JI1¹, Choi DH1, Huh SJ1, Park W1, Nam SJ2, Kim SW2, Lee JE2, Kil WH2, Im YH3, Ahn JS3, Park YH3.

Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14.

Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients

Woo HI1¹, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.

Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19.

Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology

Jung HA1¹, Park YH, Kim M, Kim S, Chang WJ, Choi MK, Hong JY, Kim SW, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.

Cancer Chemother Pharmacol. 2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.

Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer

Choi MK1¹, Park YH, Kil WH, Lee JE, Nam SJ, Ahn JS, Im YH.

Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.

Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers

Park YH1¹, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH.

Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR

Ahn MJ1¹, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM4, Massey D5, Kim M6, Shi Y7, Park K8.

Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13.

Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy

Lee H1¹, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.

Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs

Lee JY1¹, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ.

Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22.

Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma

Park LC1¹, Jeong JY2, Ji JH3, Park S3, Ahn JS3, Im YH3, Park YH3.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

Lim SH1¹, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin

Chang WJ1¹, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.

Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18.

Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy

Lee SY1¹, Im SA2, Park YH3, Woo SY4, Kim S4, Choi MK5, Chang W5, Ahn JS5, Im YH5.

Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma

Sun JM1¹, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.

Br J Cancer. 2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

Park YH1¹, Jung HA1, Choi MK1, Chang W1, Choi YL2, Do IG2, Ahn JS1, Im YH1.

J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.

Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients

Kim Y1¹, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3.

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

Choi MK1¹, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.

Cancer Res Treat. 2014 Apr;46(2):131-40. doi: 10.4143/crt.2014.46.2.131. Epub 2014 Apr 22.

A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians

Kim do Y1¹, Ahn JS2, Lee KH3, Kim YC4, Lee J5, Kim SY6.

Support Care Cancer. 2014 Mar;22(3):741-50. doi: 10.1007/s00520-013-2030-1. Epub 2013 Nov 8.

A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics

Han HS1¹, Lee KH, Lee KH, Ryu JS, Kim YC, Park SW, Oh HS, Park KT, Kwon JH, Lee PB, Lee WS, Kim YS, Ahn JB, Jeon SW, Lee SY, Seol YM, Kang JH, Yuh YJ, Oh SY, Kim SR, Ahn JS.

Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

Ahn JS1¹, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.

Lung Cancer. 2013 Aug;81(2):231-5. doi: 10.1016/j.lungcan.2013.04.011. Epub 2013 May 14.

The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer

Kim YS1¹, Sun JM, Ahn JS, Ahn MJ, Park K.

Ann Oncol. 2013 Jun;24(6):1485-90. doi: 10.1093/annonc/mds658. Epub 2013 Feb 4.

Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)

Kim HR1¹, Jung KH, Im SA, Im YH, Kang SY, Park KH, Lee S, Kim SB, Lee KH, Ahn JS, Kim SI, Sohn JH.

J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer

Lira ME1¹, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.

J Breast Cancer. 2012 Jun;15(2):239-43. doi: 10.4048/jbc.2012.15.2.239. Epub 2012 Jun 28.

Survey of the Application of the Korean Clinical Practice Recommendations on Breast Cancer Treatment: The Utility of the Korean Breast Cancer Society Guidelines

Gwak G1¹, Lee HK, Kim HJ, Lee SY, Park YL, Lee JW, Kim SG, Huh H, Shin H, Kim JR, Ahn JS, Son JH, Lee IG, Park WC, Kim SY, Han S, Lee ES; Korean Breast Cancer Society; Korea Breast Cancer Foundation.

J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Han JY1¹, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.

Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

Im SA1¹, Lee KS, Ro J, Lee ES, Kwon Y, Ahn JH, Ahn JS, Kim JH, Kang HS, Shin KH, Noh DY, Park IA, Kim SB, Im YH, Ha SW.

Support Care Cancer. 2010 Feb;19(2):297-301. doi: 10.1007/s00520-010-0825-x. Epub 2010 Mar 7.

The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study

Kim DY1¹, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY, Kim SY.

Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

Sun JM1¹, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K.

Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5.

Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)

Kim JE1¹, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY.

BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527.

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype

Yi SY1¹, Ahn JS, Uhm JE, Lim do H, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH.

Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12.

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

Chang MH1¹, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K.

Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24.

Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib

Koh Y1¹, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party.

Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719.

Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer

Lee DH1¹, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.

Oncology.?2008;74 Suppl 1:4-6. doi: 10.1159/000143211. Epub 2008 Aug 28.

Progress of cancer pain management in Korea

Lee JY1¹,?Ahn JS.